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The recent findings brought the necessity of testing the mutational status of a series of genes which had been
already identified as responsible for melanomas development and progression, such as BRAF, CKIT and PTEN: the
consequent results are, in fact, essential to guide the assessment of the novel treatment protocols based on tailored
targeted therapies. We present here the case of a 66 year-old male patient, diagnosed with an advanced melanoma
in June 2011, and treated with Dabrafenib for double mutant metastatic disease. The patient was referred to our
attention for a large exophytic malignant melanoma on the left shoulder. After complete surgical excision and
elective lymph node dissection for presence of metastatic sentinel lymph node, the patient has started high-dose
interferon alfa-2b injections as adjuvant therapy for a complete negative staging. The treatment was interrupted in
August 2011 due to the appearance of metastatic lymph nodes. Tumor burden was rapidly growing reaching in few
months the size of a tennis ball for the tumor mass located in the shoulder. Mutational study of the tumor revealed
a double BRAF mutation on V-600E and V600M. This finding incited us to enroll the patient in compassionate
Dabrafenib clinical trial. The therapy was started on may 2012 at 150 mg bid dosage. Almost surprisingly for the
rapidity of the effect, one week later the lesion on the shoulder has reduced its size by 60% and one month later it
has completely disappeared from sight. CT scan of June 2012 documented the astonishing clinical response.The last year has finally experienced a real breakthrough
in advanced melanoma therapy, that had probably been
awaited for decades: molecular targeted therapies have
been added to old and often impotent treatments in the
battle against its metastatic disease.
It is nowadays well known that prognosis is dramatic-
ally influenced by primary tumor stage and chanches to
be cured are very low in presence of non-operable meta-
static disease. In fact, metastatic melanoma faces a poor
outcome, with a predicted 5-year survival rate less than
10%, according to the metastases site and serum LDH
levels [1].
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reproduction in any medium, provided the or(MEK and mTOR pathways): the consequent results are,
in fact, essential to guide the assessment of the novel
treatment protocols based on tailored targeted therapies.
Among them, Vemurafenib ((RG 7204; Roche, Basel,
Switzerland) and Dabrafenib (GSK2118436), are the
selective inhibitors of BRAF kinase activity that competi-
tively inhibit ATP [2,3], suppressing a downstream phar-
macodynamic biomarker (pERK) in tumour cell lines. In
particular, the drug has demonstrated an antiproliferative
activity against multiple BRAF mutant tumour cell lines
and achieved biomarker suppression and tumour regres-
sion in BRAF mutant xenograft models.
At this regard we present here the case of a 66 year-old
male patient, diagnosed with an advanced melanoma in
June 2011, and treated with Dabrafenib for double mutant
metastatic disease.
The patient was referred to our attention for a 5 cm
large exophytic skin lesion on the left shoulder, that
revealed to be a malignant melanoma (Figure 1a). After
complete surgical excision and elective lymph node dis-
section for presence of metastatic sentinel lymph node,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Advanced cutaneous malignant melanoma. Large exophytic skin melanoma on the left shoulder (Panel a); Left axillary and brachial
metastatic masses (Panel b); reduction of the shoulder metastatic lesions by 60% after 1 week of Dabrafenib therapy (Panel c); Melanoma
metastatic lesions completely disappeared after less than 1 month of therapy (Panel d).
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tions (Intron) as adjuvant therapy for a complete negative
staging. The treatment was interrupted in August 2011
due to the appearance of left axillary and brachial nodu-
lar masses, that appeared as metastatic lymph nodes at
CT scan in February 2012. Tumor burden was rapidly
growing reaching in few months the size of a tennis ball
for the tumor mass located in the shoulder that deter-
mined the uncomfortable “hump” on the patient’s back
(Figure 1b).
Mutational study of the tumor revealed a double BRAF
mutation on V-600E and V600M. Preliminary evidences
showed an antiprolifetive activity of Dabrafenib also on
rare BRAF somatic mutations different from the V600E
[4,5]. This finding incited us enroll the patient in com-
passionate Dabrafenib clinical trial. The therapy was
starded on may 2012 at 150 md bid dosage. Almost sur-
prisingly for the rapidity of the effect, one week later the
lesion on the shoulder has reduced its size by 60%
(Figure 1c) and one month later it has completely
disappeared from sight (Figure 1d). CT scan of June
2012 documented the astonishing clinical response. The
patients did not experience any adverse reactions except
for nausea in the first few days of therapy.
Obviously, the therapeutic benefit improved patient
quality of life and mood. Based on previous experiences in
the use of anti-BRAF molecules we cannot be optimisticand a relapse of the disease is expected at any time,
so the patient is nowadays in constant monitoring.
While we eagerly keep monitoring the evolution of our
patient’s disease, we are awaiting the new advances in
melanoma targeted therapy. Molecular targeted therapies
(e.g. B-RAF inhibitors) have reached high response rates
but unfortunately rather short response duration (Pro-
gression Free Survival of 6 months), while Immunother-
apy showed slower but more durable results [6]. We
expect promising outcomes from both the multi-target
molecular therapy and the combination of molecular tar-
geted therapies and Immunotherapy that should provide
a long lasting outcome together with high response rates
[7]. Moreover, there are still many ongoing trials both
in mono-therapy and in combination with GSK1120212,
a MEK inhibitor, that can greatly strengthen our hopes
for a new era in melanoma treatment.
It is necessary to understand and overcome the limi-
tations of these strategies, especially those concerning
resistance mechanisms, in order to transform ephemeral
remissions in long-lasting healing.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images.
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